NanoXplore Announces Appointment of New Board Member

NanoXplore Inc. ("NanoXplore" or the "Corporation") ( TSX: GRA and OTCQX: NNXPF ), a world-leading graphene company, announces the nomination of Ms. Catherine Loubier to its Board of Directors.

The nomination of Ms. Loubier followed an extensive search process by the Corporate Governance and Nominating Committee of the Board. The Board will continue to ensure its composition is well aligned to support senior management with the execution of its new five-year strategic growth plan and with the next phase of the Company's growth.

Ms. Loubier brings significant experience and expertise to complement the capabilities of the Board, and drive shareholder value.

"I'm pleased to announce the nomination of Catherine to the Board. With her skillsets in corporate governance and leadership, she is well positioned to provide the effective oversight and direction required for NanoXplore's ambitious vision, plan, and purpose and I am confident that her presence will strengthen the ability to execute our mandate of value creation for all shareholders." said Benoît Gascon, Lead Director of the Board.

Ms. Catherine Loubier is a senior advisor to the corporate world. In her recent role as Quebec's Delegate General in New York, from February 2019 to August 2021, she was instrumental in finalizing the largest renewable hydropower contract ever with New York State. She previously served as Deputy Chief of Staff to the Premier of Quebec from October 2018 to February 2019. From 2015 to 2018, she advised business leaders in various industries, including the President and CEO of Alliance Renault Nissan Mitsubishi. She spent nearly ten years in the federal government, including as senior adviser to the 22nd Prime Minister of Canada from 2013 to 2015 and a member of the senior staff of federal ministers from 2006. She is a member of the Women's Forum New York and a board member of administration of the Canadian American Business Council and the Council for Canadian American Relations. Ms. Loubier holds a bachelor's and master's degree from the University of Quebec in Montreal, obtained in 1996, and a certificate from Harvard Business School, obtained in 2020

About NanoXplore

NanoXplore is a graphene company, a manufacturer and supplier of high-volume graphene powder for use in industrial markets. The Company provides standard and custom graphene-enhanced plastic and composite products to various customers in transportation, packaging, electronics, and other industrial sectors. NanoXplore is headquartered in Montreal, Quebec with manufacturing facilities in Canada, the United States and Europe.

For further information, please contact:

Martin Gagné
Director of Investor Relations
martin.gagne@nanoxplore.ca
Tel: 438.476.1342


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

GRA:CA,NNXPF
The Conversation (0)
Sona Nanotech

Sona Nanotech Grants Options

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce that it has granted 25,000 incentive stock options under the Company's Stock Option Plan ("Option Plan") to a consultant. Each option is exercisable into one common share at a price of $0.30 per share... Keep Reading...
Sona Nanotech

Sona Nanotech

Get access to more exclusive Nanotech Investing Stock profiles here Keep Reading...
Longeveron to Present at the Emerging Growth Virtual Conference on June 12, 2024

Longeveron to Present at the Emerging Growth Virtual Conference on June 12, 2024

Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it will participate in the Emerging Growth Virtual Conference taking place June 12-13, 2024. Details for the Company's presentation: Date: Wednesday, June 12, 2024 Time:... Keep Reading...
Veru to Present at the American Diabetes Association's 84th Scientific Sessions

Veru to Present at the American Diabetes Association's 84th Scientific Sessions

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that the Company will present two... Keep Reading...
Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor

Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor

Dr. Selvaggi was instrumental in the development and approval of lung cancer drugs Zykadia for Novartis and Opdivo for Bristol Myers Squibb CEL-SCI's Multikine immunotherapy improves the 5-year survival of head and neck cancer patients to 73% compared to 45% in controls and cuts the 5-year risk... Keep Reading...

Ventyx Biosciences Announces Positive Preclinical Data for CNS-Penetrant NLRP3 Inhibitor VTX3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory Markers

VTX3232 demonstrated improvements in body weight, systemic inflammatory biomarkers and cardiometabolic parameters in diet-induced obesity (DIO) mice Additive effects were observed for VTX3232 in combination with the GLP-1 receptor agonist semaglutide across key endpoints compared to semaglutide... Keep Reading...

Latest Press Releases

Related News